<DOC>
	<DOCNO>NCT00367471</DOCNO>
	<brief_summary>The purpose study determine optimal dose lapatinib administer carboplatin , paclitaxel , trastuzumab subject ErbB2-positive breast cancer carboplatin paclitaxel subject ErbB2-negative breast cancer .</brief_summary>
	<brief_title>Combination Of Lapatinib With Carboplatin , Paclitaxel Trastuzumab In Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : Subjects must histologically cytologicallyconfirmed invasive breast cancer Stage IV disease . Treatment Group A : Documentation ErbB2 status ( IHC 3+ FISH+ ) breast tumor specimen must demonstrate study enrollment . It request archive breast tumor tissue send central laboratory independent confirmation ErbB2 status FISH analysis . Treatment Group B : Documentation ErbB2 status ( IHC FISH ) breast tumor specimen must demonstrate study enrollment . It request archive breast tumor tissue send central laboratory independent confirmation ErbB2 status ( FISH analysis ) . Subjects must ≥18 year age . Male female Criteria female subject : Nonchildbearing potential ( i.e. , woman function ovary current document tubal ligation hysterectomy , woman postmenopausal define menstruation 12 month ) ; Childbearing potential ( i.e. , woman function ovary document impairment oviductal uterine function would cause sterility . ) This category include woman oligomenorrhoea ( severe ) , woman perimenopausal , young woman begin menstruate . These subject must negative serum pregnancy test screen agree one following : Complete abstinence intercourse two week prior administration first dose study medication 28 day final dose study medication ; Consistent correct use one follow acceptable method birth control : male partner sterile prior female subject 's entry study sole sexual partner female subject ; implant levonorgestrel ; injectable progestogen ; intrauterine device ( IUD ) document failure rate le 1 % per year ; oral contraceptive ( either combine progestogen ) ; barrier method , include diaphragm condom spermicide . Able swallow retain oral medication . Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Subjects may measurable lesion ( ) accord RECIST criterion per protocol . Patients metastases bone also eligible study enrollment . Subjects stable CNS metastasis leptomeningeal involvement eligible take oral steroid enzymeinducing anticonvulsant . Subjects receive prior radiotherapy must complete radiotherapy treatment least four week enrollment recover treatmentrelated toxicity . Subjects must leave ventricular ejection fraction ( LVEF ) ≥ 50 % ≥ low limit normal institution base Multiplegated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) . Subjects must adequate hematological , hepatic , renal function . Hemoglobin least 9 gm/dL Absolute granulocyte count least 1,500/mm3 ( 1.5 x 109/L ) Platelets least 100,000/mm3 ( 100 x 109/L ) Total bilirubin 2.5mg/dL ALT and/or AST 1.5 time upper limit normal range ( ULN ) alkaline phosphatase 2.5 time ULN . For subject liver metastasis , AST ALT 5 time ULN may enrol total bilirubin le 1.5 time ULN ALT AST check twice interval least 2 week prior treatment determine liver function stable . Calculated creatinine clearance ( ClCr ) least 50mL/min accord formula Cockcroft Gault per protocol . Subjects receive taxane part adjuvant neoadjuvant therapy eligible recurrence disease six month completion treatment . Subjects receive trastuzumab part adjuvant therapy eligible recurrence disease six month completion treatment . Subjects must provide sign write informed consent . Exclusion criterion : Subject peripheral neuropathy Grade 2 high ; Subject prior systemic cytotoxic chemotherapy metastatic locally recurrent disease . Also , subject prior chemotherapy adjuvant neoadjuvant set anthracycline anthracenedionecontaining regimen cumulative dos ≥ 360mg/m2 doxorubicin , ≥ 720mg/m2 epirubicin , ≥ 72 mg/m2 mitoxantrone . Patients prior hormonal therapy ( y ) eligible . Subjects prior systemic investigational drug within past 30 day topical investigational drug within past seven day ; Subjects uncontrolled symptomatic angina , arrhythmia . Subjects Class II IV heart failure define New York Heart Association ( NYHA ) functional classification system . Subjects know immediate delay hypersensitivity untoward reaction paclitaxel , trastuzumab , carboplatin , related compound , drug chemically relate lapatinib . These include aminoquinazolines , gefitinib ( Iressa ) , erlotinib ( Tarceva ) , chemicallyrelated compound . Has malabsorption syndrome , disease affect gastrointestinal function , resection stomach small bowel . Subjects take prohibited medication per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>lapatinib</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>carboplatin</keyword>
	<keyword>breast cancer</keyword>
</DOC>